CLARITIN LIQUID CAPSULES
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
10-05-2019
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
LORATADINE
Tilgængelig fra:
BAYER INC
ATC-kode:
R06AX13
INN (International Name):
LORATADINE
Dosering:
10MG
Lægemiddelform:
CAPSULE
Sammensætning:
LORATADINE 10MG
Indgivelsesvej:
ORAL
Enheder i pakken:
24/36/84
Recept type:
OTC
Terapeutisk område:
SECOND GENERATION ANTIHISTAMINES
Produkt oversigt:
Active ingredient group (AIG) number: 0120416001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2014-12-05
Produktets egenskaber
PRODUCT MONOGRAPH
CLARITIN
® LIQUID CAPSULES LORATADINE CAPSULES, 10 MG
HISTAMINE H
1
RECEPTOR ANTAGONIST
Bayer Inc.
DATE OF PREPARATION:
2920 Matheson Blvd. E
May 10
th
, 2019
Mississauga, ON
L4W 5R6
Control #: 225631
® TM see www.bayer.ca/tm-mc
_ _
_CLARITIN LIQUID CAPSULES _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
………………………………….…...
3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL
USE.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
3
ADVERSE REACTIONS
......................................................................................................
4
DRUG INTERACTIONS
.......................................................................................................
6
DOSAGE AND ADMINISTRATION
...................................................................................
7
OVERDOSAGE
.....................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 7
STORAGE AND STABILITY
..............................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
............................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 9
PART II: SCIENTIFIC INFORMATION
…………………………………………………….
. 10
PHARMACEUTICAL INFORMATION
............................................................................
10
CLINICAL
TRIALS...........................................................
Læs hele dokumentet
